跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 321 条关于
“Nimbus”
全部
321
临床试验
278
药物
10
机构
4
资讯
29
去年
Nimbus Therapeutics Advances Oncology Pipeline with WRN Inhibitor NDI-219216
去年
Nimbus Therapeutics Names Abbas Kazimi as New CEO in Planned Leadership Transition
去年
Nimbus Therapeutics' HPK1 Inhibitor Shows Promise in Advanced Solid Tumors
去年
Nimbus Therapeutics' HPK1 Inhibitor Shows Promise in Advanced Renal Cell Carcinoma
9个月前
Nimbus Therapeutics Completes Dose Escalation for Novel WRN Inhibitor NDI-219216 in MSI-H Tumors
9个月前
Strand Therapeutics Appoints Former Nimbus CEO Jeb Keiper to Board as Company Advances Programmable mRNA Platform
去年
Nimbus Therapeutics Initiates First-in-Human Trial of NDI-219216 for MSI-H Tumors Resistant to Standard Therapies
7个月前
Nimbus Therapeutics Advances Novel SIK2 Inhibitors for Inflammatory Bowel Disease with Dual Anti-Inflammatory and Mucosal Healing Mechanism
上个月
LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board as Oral TIM-3/TIM-4 Agonist Advances Through Phase 1b Trials
去年
Nimbus Therapeutics' NDI-101150, an Oral HPK1 Inhibitor, Shows Promise in Early Clinical Trials for Advanced Solid Tumors
第 1 页,共 3 页
上一页
下一页